IE58015B1 - Tigogenin-cellobioside for treating hypercholesterolemia and arteriosclerosis - Google Patents

Tigogenin-cellobioside for treating hypercholesterolemia and arteriosclerosis

Info

Publication number
IE58015B1
IE58015B1 IE190484A IE190484A IE58015B1 IE 58015 B1 IE58015 B1 IE 58015B1 IE 190484 A IE190484 A IE 190484A IE 190484 A IE190484 A IE 190484A IE 58015 B1 IE58015 B1 IE 58015B1
Authority
IE
Ireland
Prior art keywords
compound
tigogenin
anomer
cellobioside
formula
Prior art date
Application number
IE190484A
Other languages
English (en)
Other versions
IE841904L (en
Original Assignee
Oregon Medical Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon Medical Res Found filed Critical Oregon Medical Res Found
Publication of IE841904L publication Critical patent/IE841904L/en
Publication of IE58015B1 publication Critical patent/IE58015B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0013—Details of inhalators; Constructional features thereof with inhalation check valves
    • A61M15/0015—Details of inhalators; Constructional features thereof with inhalation check valves located upstream of the dispenser, i.e. not traversed by the product
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0013—Details of inhalators; Constructional features thereof with inhalation check valves
    • A61M15/0016—Details of inhalators; Constructional features thereof with inhalation check valves located downstream of the dispenser, i.e. traversed by the product
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0086—Inhalation chambers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Cephalosporin Compounds (AREA)
IE190484A 1984-04-20 1984-07-23 Tigogenin-cellobioside for treating hypercholesterolemia and arteriosclerosis IE58015B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/602,298 US4602005A (en) 1982-05-17 1984-04-20 Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis

Publications (2)

Publication Number Publication Date
IE841904L IE841904L (en) 1985-10-20
IE58015B1 true IE58015B1 (en) 1993-06-16

Family

ID=24410793

Family Applications (1)

Application Number Title Priority Date Filing Date
IE190484A IE58015B1 (en) 1984-04-20 1984-07-23 Tigogenin-cellobioside for treating hypercholesterolemia and arteriosclerosis

Country Status (16)

Country Link
US (1) US4602005A (index.php)
EP (1) EP0159431B1 (index.php)
JP (1) JPS60224697A (index.php)
KR (1) KR940002114B1 (index.php)
AT (1) ATE42959T1 (index.php)
AU (1) AU580005B2 (index.php)
CA (1) CA1246544A (index.php)
DE (1) DE3478114D1 (index.php)
DK (2) DK165839C (index.php)
ES (1) ES534553A0 (index.php)
FI (2) FI82253C (index.php)
HU (1) HUT37802A (index.php)
IE (1) IE58015B1 (index.php)
NO (1) NO842990L (index.php)
NZ (1) NZ208961A (index.php)
ZA (1) ZA845690B (index.php)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4602005A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis
US4865850A (en) * 1986-09-08 1989-09-12 See/Shell Biotechnology, Inc. Dietary fat reduction
US5010185A (en) * 1989-06-13 1991-04-23 Pfizer Inc. Processes for tigogenin beta-cellobioside
US5091192A (en) * 1990-01-16 1992-02-25 Natur-All Systems, Inc. Bile salts permanently bound to insoluble cellulose as a dietary supplement
CA2079544A1 (en) * 1991-10-04 1993-04-05 Adam Weislaw Mazur Cholesterol lowering compounds
DE69225233T2 (de) * 1991-10-04 1998-11-19 Procter & Gamble Cholesterinsenkende Verbindungen und Verfahren zu ihrer Herstellung
HUT67035A (en) * 1991-11-25 1995-01-30 Pfizer New process for the production of steroidal glycosides derivatives
US5294703A (en) * 1992-05-01 1994-03-15 Eastman Kodak Company Process for preparing α-D-cellobiose octaacetate
HUT68885A (en) * 1992-06-26 1995-08-28 Pfizer New process for steroidal peracyl glycosides
CA2138016A1 (en) * 1992-06-26 1994-01-06 Kathleen D. Goggin Steroidal beta-o-cellobioside heptaalkanoate process
AU4226593A (en) * 1992-06-26 1994-01-24 Pfizer Inc. Steroidal glycosides for treating hypercholesterolemia
US5530107A (en) * 1992-10-15 1996-06-25 Pfizer Inc. Method for making steroidal peracyl glycosides
EP0696292A1 (en) * 1993-04-28 1996-02-14 Pfizer Inc. Spirostanyl glycosidal crystalline monohydrate
US5502038A (en) * 1993-06-21 1996-03-26 Medical Research Foundation Of Oregon Cholesterol sequestrant glycosides that inhibit intestinal cholesterol absorption
WO1995000158A1 (en) * 1993-06-25 1995-01-05 Bio-Sphere Technology Dietary supplement incorporating beta-sitosterol and pectin
ES2074006B1 (es) * 1993-07-05 1996-03-16 Pfizer Glicosidos esteroidales para tratar hipercolesterolemia.
AU7948494A (en) * 1993-12-28 1995-07-17 Pfizer Inc. Steroidal glycosides
US5607841A (en) * 1994-06-20 1997-03-04 Lipinski; Boguslaw Preparation and proteolytic degradation of a macromolecular protein complex from fibrinogen
EP0782451A1 (en) * 1994-09-20 1997-07-09 Pfizer Inc. Combination of a cholesterol absorption inhibitor and a cholesterol synthesis inhibitor
WO1996038466A1 (en) * 1995-05-29 1996-12-05 Pfizer Inc. Steroidal glycosides
US5698527A (en) * 1995-08-08 1997-12-16 Merck & Co., Inc. Steroidal glycosides as antihyperlipidemic agents
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
ID26989A (id) * 1998-03-26 2001-02-22 Phytopharm Plc Smilagenin dan anzurogenin-d untuk pengobatan penyakit alzheimer
GB9923076D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB9923077D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB0000228D0 (en) * 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en) * 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
AR032403A1 (es) * 2001-01-26 2003-11-05 Schering Corp Combinaciones de inhibidor(es) de la absorcion de esterol con modificador(es) sanguineos para tratar cuadros vasculares
DE60212801T2 (de) * 2001-01-26 2007-02-01 Schering Corp. Verwendung azetidinone-substituierter verbindungen zur behandlung der sitosterolhämie
MXPA03006724A (es) * 2001-01-26 2003-10-24 Schering Corp Combinaciones de inhibidor(es) de absorcion de esterol con agente(s) cardiovascular(es) para el tratamiento de condiciones vasculares.
EP1671650A1 (en) * 2001-01-26 2006-06-21 Schering Corporation Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
HUP0303915A3 (en) * 2001-01-26 2012-12-28 Merck Sharp & Dohme Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
PT1363668E (pt) * 2001-01-26 2007-11-07 Schering Corp Combinaçoes de sequestrante(s) de ácidos biliares e inibidor(es) de absorção de esterol e tratamento de indicações vasculares
GB0107822D0 (en) * 2001-03-28 2001-05-23 Phytopharm Plc Sapogenin derivatives their synthesis and use methods based upon their use
AU2002308778A1 (en) * 2001-05-25 2002-12-09 Schering Corporation Use of azetidinone substituted derivatives in the treatment of alzheimer's disease
US20030119808A1 (en) * 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
ES2312624T3 (es) * 2001-09-21 2009-03-01 Schering Corporation Metodos para tratar o prevenir la inflamacion vascular usando un inhibidor (inhibidores) de la absorcion de esterol.
ATE345793T1 (de) * 2001-09-21 2006-12-15 Schering Corp Behandlung von xanthom mittels azetidinon- derivate als hemmer der sterol absorption
US7056906B2 (en) * 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US20050130948A1 (en) * 2002-03-27 2005-06-16 Daryl Rees Therapeutic methods and uses of sapogenins and their derivatives
KR101130212B1 (ko) * 2002-03-27 2012-04-13 파이토팜 피엘씨 사포게닌 및 그 유도체의 치료 방법 및 사용법
US7560449B2 (en) * 2002-11-06 2009-07-14 Schering Corporation Methods and therapeutic combinations for the treatment of demyelination
CN1756756A (zh) * 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
US7235543B2 (en) 2003-03-07 2007-06-26 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CN1756755A (zh) * 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
WO2005046797A2 (en) * 2003-11-05 2005-05-26 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
GB0329667D0 (en) * 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
AU2003300732A1 (en) * 2003-12-31 2005-07-21 Council Of Scientific And Industrial Research Isolation of tigogenin pentaglycoside from chlorophytum nimonii
US7160866B2 (en) 2004-03-22 2007-01-09 Council Of Scientific And Industrial Research Isolation of tigogenin pentaglycoside from Chlorophytum nimonii

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2759171A1 (de) * 1977-12-31 1979-07-12 Roecar Holdings Nv Arzneimittel mit wirkung als prostaglandinsynthetaseninhibitor
DE2926463A1 (de) * 1978-07-05 1980-01-24 Roecar Holdings Nv Spiroketaline und ihre verwendung
US4260603A (en) * 1979-01-02 1981-04-07 Pegel Karl H Sterol glycoside with activity as prostaglandin synthetase inhibitor
US4242502A (en) * 1979-04-20 1980-12-30 United States Of America Enhancement of cholesterol combining properties of saponins
US4602005A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis
US4602003A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia

Also Published As

Publication number Publication date
DK361084A (da) 1985-10-21
EP0159431A3 (en) 1986-01-08
EP0159431B1 (en) 1989-05-10
DK361084D0 (da) 1984-07-23
JPH0456840B2 (index.php) 1992-09-09
JPS60224697A (ja) 1985-11-09
NZ208961A (en) 1988-01-08
DK166213C (da) 1993-08-16
KR940002114B1 (ko) 1994-03-17
DK14892A (da) 1992-02-06
FI842935L (fi) 1985-10-21
US4602005A (en) 1986-07-22
HUT37802A (en) 1986-02-28
EP0159431A2 (en) 1985-10-30
FI82253C (fi) 1991-02-11
DK165839B (da) 1993-01-25
FI87792C (fi) 1993-02-25
FI82253B (fi) 1990-10-31
KR850007432A (ko) 1985-12-04
ZA845690B (en) 1986-03-26
ATE42959T1 (de) 1989-05-15
IE841904L (en) 1985-10-20
NO842990L (no) 1985-10-21
DK166213B (da) 1993-03-22
ES8601233A1 (es) 1985-11-16
DE3478114D1 (en) 1989-06-15
CA1246544A (en) 1988-12-13
FI842935A0 (fi) 1984-07-23
ES534553A0 (es) 1985-11-16
FI900531A0 (fi) 1990-02-02
DK165839C (da) 1993-06-21
FI87792B (fi) 1992-11-13
AU3097784A (en) 1985-10-24
AU580005B2 (en) 1988-12-22
DK14892D0 (da) 1992-02-06

Similar Documents

Publication Publication Date Title
EP0159431B1 (en) Tigogenin-cellobioside and its heptaacetate, methods for their preparation, and pharmaceutical compositions containing tigogenin-cellobioside
CA1280369C (en) Pharmaceutical with anti-tumor effect
US5023249A (en) Fertility drug and method of producing the same
EP0488513B1 (en) Use of dioxabicyclo [3.3.0]octane derivatives for the manufacture of a medicament for inhibiting the metabolism of cholesterol.
JPH0730113B2 (ja) シクロスポリン誘導体
WO1995010527A1 (en) 3,17-dihydroxy-3,7,16 and/or 17-methyl-androst-5-ene compounds, derivatives thereof, and their use
DE3872234T2 (de) Zyklische kohlenwasserstoffe mit aminoalkyl-seitenkette.
US4960595A (en) Lipid membrane structures
US5789439A (en) Pharmaceutical use of forskolin derivatives
Byers et al. Further Studies Concerning Glucagon-lnduced Hypocholesterolemia
US6136800A (en) 17-Difluoromethylene-estratrienes
US5496806A (en) Glycoside compounds and production and use thereof
EP0222912A1 (en) Agent for treating arteriosclerosis
CZ410498A3 (cs) Polyolové sukcináty a jejich farmaceutické formulace
EP0087744B1 (en) Lipid metabolism improving agents
US5028438A (en) Biologically active agent having anti-hypertensive activity in mammals
DE3787371T2 (de) Biologisch aktives mittel.
EP0933080A1 (en) Remedy or preventive for hyperlipemia
EP0510197A1 (en) Fat emulsion
JPH10503191A (ja) テトラサイクリックトリテルペン
US3655886A (en) Pharmacologically effective substance and process for preparing it
EP0799235A1 (en) Methods for the preparation of pure homologous series of mono to tetra fatty acyl esters of sugars; characterization of one antitumor component as maltose 1, 6, 6' tripalmitate: and pharmaceutical formulations useful in the treatment of cancer.
AT390880B (de) Pharmazeutische verwendung einer 8-chlorobenzothiazepinverbindung
KR830000630B1 (ko) 스피로케탈-스테로이드 글리코 사이드의 제조방법
EP0489933A1 (en) Bile alcohol and drug containing the same as active ingredient

Legal Events

Date Code Title Description
MM4A Patent lapsed